期刊文献+

英夫利昔单抗治疗幼年特发性关节炎的疗效 被引量:9

Clinical study of infliximab in treatment of patients with juvenile idiopathic arthritis
原文传递
导出
摘要 目的研究英夫利昔单抗治疗幼年特发性关节炎(JIA)患儿的临床疗效、不良反应及转归。方法32例英夫利昔单抗组JIA患儿于0、2、6、ld、22、30周静脉输注英夫利昔单抗3~8mg/(kg·次),按治疗剂量不同分为≥5mg/(kg·次)大剂量治疗组和〈5mg/(kg·次)小剂量治疗组。比较英夫利昔单抗组和30例JIA常规治疗(对照组)患儿压痛关节数(TJC)、肿胀关节数(SJC)、红细胞沉降率(ESR)、C-反应蛋白(CRP)、患者自身综合评分(GH)、疾病活动度评分(DAS)28评分和不良反应,分析英夫利昔单抗的疗效、不良反应和预后。结果英夫利昔单抗治疗可改善JIA患儿TJC、SJC、ESR、GH、CRP和DAS28评分。英夫利昔单抗组JIA患儿的SJC在2周最先开始下降,6周时TJC、ESR、GH和DAS28评分开始下降,TJC、SJC、ESR、CRP和DAS28评分持续下降至22周无进行性下降,GH持续下降至30周。英夫利昔单抗大剂量治疗组患儿ESR、GH和CRP均低于小剂量治疗组(t=2.14、3.04、2.33,P=0.04、0.01、0.04),2组TJC、SJC、DAS28评分和近期不良反应发生率比较差异无统计学意义。英夫利昔单抗组2例(6.25%)患儿治疗失败,9例(28.13%)患儿持续英夫利昔单抗治疗达46~62周,7例(21.88%)患儿于30周后停用英夫利昔单抗且关节及炎症反应控制良好,14例(43.75%)患儿停用英夫利昔单抗后病情加重,重新开始治疗;1例患儿在停用英夫利昔单抗后发生重症水痘感染,死亡。结论英夫利昔单抗治疗能改善JIA患儿关节症状、炎症指标和DAS28评分,是近期安全、有效的JIA治疗手段。 Objective To explore the clinical efficacy, adverse effect and prognosis of infliximab in treatment of the patients with juvenile idiopathic arthritis (JIA). Methods Thirty-two cases of infliximab-treated JIA patients and 30 cases of JIA control patients were investigated in this prospective study, and their tender joint count (TJC) , swollen joint count (SJC),erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),visual analog scale for general health ( GH), disease activity score (DAS) 28, as well as adverse reactions of treatment and follow-up outcomes were analyzed. The infliximab-treated patients were intravenously infused with infliximab at the low dose of 〈 5 mg/ (kg·time) or the high dose of ≥5 mg/( kg·time) in 0,2nd ,6th ,14th ,22nd ,30th week. The JIA control patients were treated wilh conventional therapy. Results The treatment of infliximab ameliorated the TJC, SJC, ESR, GH, CRP and DAS28 of JIA patients. In the dynamical analysis of these clinical indexes of the infliximab-treated JIA patients,the in- dex of SJC was found to fall firstly in the 2nd week,the indexes of TJC,ESR,GH and DAS28 were found to decline se- condly at 6th week, the indexes of TJC, SJC, ESR, CRP and DAS28 continued dropping till 22nd week, and only the index of GH progressively declined to 30th week. The high-dose infliximab-treated group had lower levels of ESR, GH and CRP than the low-dose infliximab-treated group (t = 2. 14,3.04,2. 33, P = 0. 04,0. 01,0. 04 ). But there were no statistical difference in TJC,SJC, DAS28 and the incidence of recent adverse reactions between the high and low infliximab dose groups. In the infliximab treated group,2 cases of patients (6.25%) failed in the therapy of infliximab;9 cases of pa- tients (28.13%) continued therapy with infliximab to 46th -62nd week; 7 cases of patients (21.88%) stopped thera- py with infliximab in the 30th week had good improvement of joint symptoms and inflammatory indexes;14 cases of pa- tients (43.75%) relapsed and retreated by infliximab after cease the first course of treatment ; 1 case of patient died of severe chickenpox infection after therapy with infliximab was ceased. Conclusions Infliximab can alleviate the joint symptoms,inflammatory indexes and DAS28 of JIA patients,and is an effective and safe therapy for JIA patients in the short-term study.
出处 《中华实用儿科临床杂志》 CAS CSCD 北大核心 2014年第9期655-658,共4页 Chinese Journal of Applied Clinical Pediatrics
关键词 幼年特发性关节炎 英夫利昔单抗 治疗 Juvenile idiopathic arthritis Infliximab Therapy
  • 相关文献

参考文献19

二级参考文献116

  • 1王峥嵘,张玉林,苏英姿,王天有,崔晏春.膝关节超声检查在幼年类风湿性关节炎诊断中的价值[J].实用儿科临床杂志,2004,19(8):660-661. 被引量:2
  • 2沈降,孙慧敏,田恩江.抗肿瘤坏死因子-α治疗葡萄膜炎的研究现状[J].国外医学(眼科学分册),2005,29(2):96-99. 被引量:5
  • 3杨培增.葡萄膜炎的研究进展[J].中华眼科杂志,2005,41(12):1149-1152. 被引量:39
  • 4李永柏,胡坚.巨噬细胞活化综合征专题讨论会纪要[J].中华儿科杂志,2006,44(11):831-832. 被引量:21
  • 5Crane IJ,Forrester JV.Th1and Th2lymphocytes in autoimmune disease[J].Crit Rev Immunol,2005,25(2):75-102.
  • 6Luger D,Caspi RP.New perspectives on effector mechanisms in uveitis[J].Semin Immunopathol,2008,30(2):135-143.
  • 7Diaz-Llopis M,Gallego-Pinazo R,Garcia-Delpech S,Salom-Alonso D.General principles for the treatment of non-infectious uveitis[J].Inflamm Allergy Drug Targ,2009,9(4):260-265.
  • 8Galor A,Margolis R,Brasil OM,Perez VL,Kaiser PK,Sears JE,et al.Adverse events after intravitreal triamcinoline in patients w ith and w ithout uveitis[J].Ophthalmology,2007,114(10):1912-1918.
  • 9Kim TJ,Kim N,Kang HJ,Kim EO,Kim ST,Ahn HS,et al.FK506causes cellular and functional defects in human natural killer cells[J].J Leuk Biol,2010,88(6):1089-1097.
  • 10O’Shea JJ,Ma A,Lipsky P.Cytokines and autoimmunity[J].Nat Rev Im m unol,2002,2(1):37-45.

共引文献48

同被引文献139

  • 1赵慧,汪静,杨喜云,郭建,王宏沛,沈海丽.英夫利昔单抗治疗强直性脊柱炎累及颞颌关节一例[J].中华临床医师杂志(电子版),2011,5(7):2162-2163. 被引量:1
  • 2李晓红,舒健翔,王宏伟.儿童风湿性疾病的肺部表现[J].国外医学(儿科学分册),2003,30(6):333-335. 被引量:6
  • 3于晓敏,刘新民.肺功能检测在间质性肺疾病中的作用[J].国外医学(呼吸系统分册),2005,25(5):369-371. 被引量:16
  • 4甄小芳,马嵩春,幺远.幼年特发性关节炎95例的预后[J].实用儿科临床杂志,2006,21(21):1482-1483. 被引量:7
  • 5Swart JF, de Roock S, Wulffraat NM. What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis? [ J ]. Arthritis Res Ther, 2013,15 (3) : 213.
  • 6Oen K, Mallcson PN, Calbral QA, et al. Disease course and out- come of juvenile rheumatoid arthritis in a mutlicenter cohort [J]. J Rheumatol, 2002,29 : 1989-1999.
  • 7Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome [J]. Rheumatol- ogy, 2002,41 (12) : 1428-1435.
  • 8Otten MH, Anink J, Prince FH, et al. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis : results of the Dutch National Arthritis and Biologics in Children Register [ J ]. Ann Rheum Dis, 2015,74 (7) : 1379-1386.
  • 9Ito H, Kojima M, Nishida K, et al. Postoperative complications in patients with rheumatoid arthritis using a biological agent- asystematic review and meta-analysis [J]. Mod Rheumatol, 2015,25 (5):672-678.
  • 10Feldmann M, Brennan FM, Elliott M, et al. TNF alpha as a thera- peutic target in rheumatoid arthritis [J]. Circ Shock, 1994, 43 (4) : 179-184.

引证文献9

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部